Myelodysplastic Syndromes: Phase 1 Trial Results Find Potential in New Combination Therapy
source: pixabay.com

Myelodysplastic Syndromes: Phase 1 Trial Results Find Potential in New Combination Therapy

According to a story from GlobeNewswire, the biopharmaceutical company Onconova Therapeutics, Inc. has recently published results from a phase 1 clinical trial that was sponsored by the company. This trial…

Continue Reading Myelodysplastic Syndromes: Phase 1 Trial Results Find Potential in New Combination Therapy
$6.75 Million in Grants Sets the Stage for the Next Level of Blood Cancer Treatments
source: pixabay.com

$6.75 Million in Grants Sets the Stage for the Next Level of Blood Cancer Treatments

  After forty years of research to counter or cure acute myeloid leukemia and other blood cancers, a few years ago the medical community exploded with eight new cancer drugs.…

Continue Reading $6.75 Million in Grants Sets the Stage for the Next Level of Blood Cancer Treatments
International Panel Gives Expert Advice on the Management of COVID-19 and Blood Cancers
source: pixabay.com

International Panel Gives Expert Advice on the Management of COVID-19 and Blood Cancers

  COVID-19 has now taken hold in over one hundred eighty countries. According to a recent article in The Lancet, in May of 2020, the United States reported the highest…

Continue Reading International Panel Gives Expert Advice on the Management of COVID-19 and Blood Cancers
New Investigative Therapy for Acute Myeloid Leukemia and Myelodysplastic Syndromes is Being Investigated
source: pixabay.com

New Investigative Therapy for Acute Myeloid Leukemia and Myelodysplastic Syndromes is Being Investigated

Antigen-specific T-cell therapy is an innovative treatment option which uses immune cells to combat cancer cells. AdventHealth is the very first in the world to use this treatment for patients…

Continue Reading New Investigative Therapy for Acute Myeloid Leukemia and Myelodysplastic Syndromes is Being Investigated
Novel Immunotherapy Treatment for AML and MDS Developed by AdventHealth
source: pixabay.com

Novel Immunotherapy Treatment for AML and MDS Developed by AdventHealth

Orlando-based healthcare company AdventHealth developed a novel immunotherapy treatment designed to treat patients with AML and MDS whose conditions failed to respond to other treatments. In addition, the organization is…

Continue Reading Novel Immunotherapy Treatment for AML and MDS Developed by AdventHealth
A SF3B1 Mutation May Cause A New Subset of Myelodysplastic Syndromes
source: pixabay.com

A SF3B1 Mutation May Cause A New Subset of Myelodysplastic Syndromes

Genetic research is a burgeoning and exciting field. With the discovery of new genetic mutations and variants comes a deeper understanding of rare diseases and their subtypes. According to Cancer…

Continue Reading A SF3B1 Mutation May Cause A New Subset of Myelodysplastic Syndromes
Researchers Discover Method to Predict Survival in Low-Risk Myelodysplastic Syndromes
source: pixabay.com

Researchers Discover Method to Predict Survival in Low-Risk Myelodysplastic Syndromes

A recent study published in Blood Cancer Journal has established a new method for effectively predicting survival outcomes for patients with low-risk myelodysplastic syndromes (MDS). The method is known as the…

Continue Reading Researchers Discover Method to Predict Survival in Low-Risk Myelodysplastic Syndromes
Myelodysplastic Syndromes (MDS) Genetic Subtypes have Been Identified
source: pixabay.com

Myelodysplastic Syndromes (MDS) Genetic Subtypes have Been Identified

A new study published in Blood has found different genetic variants of myelodysplastic syndromes (MDS). The most common of these is called SF3B1, which occurs in around 1 in every 5 patients. It…

Continue Reading Myelodysplastic Syndromes (MDS) Genetic Subtypes have Been Identified
FDA Approves New Treatment for Anemia Linked to Myelodysplastic Syndromes
source: pixabay.com

FDA Approves New Treatment for Anemia Linked to Myelodysplastic Syndromes

According to a story from BioSpace, Acceleron Pharma Inc. and Bristol Myers Squibb have announced recently that the US Food and Drug Administration (FDA) has recently approved a new drug…

Continue Reading FDA Approves New Treatment for Anemia Linked to Myelodysplastic Syndromes

MEDALIST Trial: The Need for Blood Transfusions Was Reduced in Myelodysplastic Syndrome Patients

Dr. Pierre Fenaux, of Hôpital Saint Louis, Paris and lead author of the MEDALIST trial, told Ash Clinical News that treatment with the investigational drug, luspatercept, improved the rate of…

Continue Reading MEDALIST Trial: The Need for Blood Transfusions Was Reduced in Myelodysplastic Syndrome Patients
Questions for COVID-19: Should Cancer Patients Attend Appointments?
Photo by National Cancer Institute on Unsplash

Questions for COVID-19: Should Cancer Patients Attend Appointments?

  In a period of unprecedented changes, it is understandable that people may question what their lives may look like moving forward. COVID-19 has now spread to 196 countries and…

Continue Reading Questions for COVID-19: Should Cancer Patients Attend Appointments?
Elderly Patients with Myelodysplastic Syndromes can Have Successful Transplants
source: pixabay.com

Elderly Patients with Myelodysplastic Syndromes can Have Successful Transplants

By Rachel Whetstone from In The Cloud Copy Many patients with myelodysplastic syndromes (MDS) are elderly when they’re diagnosed with the disease. Although stem cell transplants are often thought to…

Continue Reading Elderly Patients with Myelodysplastic Syndromes can Have Successful Transplants
ICYMI: An Observational Blood Cancer Study is Starting to Recruit Patients
source: pixabay.com

ICYMI: An Observational Blood Cancer Study is Starting to Recruit Patients

According to a story from Financial Buzz, the precision oncology company Notable has recently announced that it has opened enrollment for a new observational clinical trial that will focus on…

Continue Reading ICYMI: An Observational Blood Cancer Study is Starting to Recruit Patients
TrialJectory is a New Website Helping to Match Cancer Patients to Clinical Trials
source: pixabay.com

TrialJectory is a New Website Helping to Match Cancer Patients to Clinical Trials

TrialJectory is an organization working to match bladder, breast, colorectal, melanoma, myelodysplastic syndromes (MDS), and other cancer patients with the clinical trial that is right for them. They have successfully raised…

Continue Reading TrialJectory is a New Website Helping to Match Cancer Patients to Clinical Trials

Experimental Myelodysplastic Syndrome Treatment Receives Breakthrough Therapy Designation

  A drug created by Agios Pharmaceuticals, TIBSOVO, was recently granted the Breakthrough Therapy designation by the FDA for the treatment of relapsed or refractory myelodysplastic syndrome (MDS) with an…

Continue Reading Experimental Myelodysplastic Syndrome Treatment Receives Breakthrough Therapy Designation
FDA Committee to Hold Review for Reblozyl as a Treatment for Myelodysplastic Syndromes
source: pixabay.com

FDA Committee to Hold Review for Reblozyl as a Treatment for Myelodysplastic Syndromes

According to a story from BioPortfolio, Acceleron Pharma and the Bristol-Myers Squibb Company have announced recently that the US Food and Drug Administration (FDA) will review the supplemental Biologics License…

Continue Reading FDA Committee to Hold Review for Reblozyl as a Treatment for Myelodysplastic Syndromes
Experimental Treatment for Pancreatic Cancer has Earned Orphan Drug Designation
source: pixabay.com

Experimental Treatment for Pancreatic Cancer has Earned Orphan Drug Designation

According to a story from BioSpace, the biopharmaceutical company CrystalGenomics, Inc. recently announced that the US Food and Drug Administration (FDA) has granted the company's investigational drug candidate CG-745 Orphan…

Continue Reading Experimental Treatment for Pancreatic Cancer has Earned Orphan Drug Designation

FDA Approves an Experimental Treatment of Various Blood Malignancies for Clinical Trials

According to a story from First World Pharma, the biopharmaceutical company Mustang Bio, Inc. recently announced that the US Food and Drug Administration (FDA) has approved their investigational new drug…

Continue Reading FDA Approves an Experimental Treatment of Various Blood Malignancies for Clinical Trials
Close Menu